Stage I Lung Adenocarcinoma With Later Kidney Metastases Responding to Osimertinib
This lung cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Subtype
- Adenocarcinoma
- Biomarkers
- EGFR L858R mutation; RB1 mutation; MAP3K1 mutation; PD-L1 negative
- Sex
- female
- Spread to
- kidneys, peritoneal lymph nodes
- Treatment
- surgery and targeted therapy
- Outcome
- Responding Well
Treatment course, step by step
- Underwent right upper lobectomy with lymph-node dissection in May 2021 and received no adjuvant treatment.
- Started osimertinib after biopsy-confirmed kidney metastases were found in April 2023.
- Continued osimertinib after a partial response.
What happened, in summary
A 59-year-old woman had a right upper-lung nodule found during a health examination in May 2021. Surgery the next day removed the right upper lobe and nearby lymph nodes. Pathology confirmed Stage I invasive lung adenocarcinoma with clear margins and no involved lymph nodes. She did not need postoperative treatment and entered regular surveillance.
In April 2023, PET-CT found several masses in both kidneys as well as metastatic lymph nodes in the peritoneal area. Biopsy of the largest kidney mass showed markers matching lung adenocarcinoma rather than a new kidney cancer, confirming metastatic recurrence and Stage IV disease.
Genetic testing of both the original lung tumor and the kidney metastasis found an EGFR L858R mutation along with RB1 and MAP3K1 alterations. PD-L1 testing was negative.
She started osimertinib. After 6 weeks, follow-up CT showed a partial response. She continued osimertinib and was alive at the latest documented follow-up.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 4 Lung Cancer 384 stories
- Stage 4 EGFR Mutation Lung Cancer 74 stories
- EGFR Mutation Lung Cancer 112 stories
- Lobectomy for Lung Cancer 149 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer